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PATIENT REGISTRIES: PATIENT CONSENT WHEN CHILDREN 
BECOME ADULTS 
LESLIE P. FRANCIS* 
I.  INTRODUCTION 
Patient registries are now a widespread and valuable feature of the 
medical landscape. Registries are an enormously useful resource for 
information about the clinical course of diseases, treatment safety and 
efficacy, care quality, and comparative effectiveness of interventions. They 
collect data from both patients and their medical records, sometimes only at 
a single point in time, but often on a continuing basis. For many registries, 
data will be coded but individual identities will be preserved so that the 
coding could be reversed in appropriate circumstances for clinical care or 
for research. Registries serve to identify less frequent events and events that 
may only appear over time. They also may be used as a complement to or 
even replacement for the randomized clinical trial as a basis for studying 
drugs, devices, or other medical interventions. They are particularly useful in 
patient populations such as children who cannot give their own consent to 
inclusion in interventional clinical trials or pregnant women who are typically 
excluded from these studies. 
Many registries involve diseases that manifest in infancy or early 
childhood, at a point before patients can be expected to give assent or 
consent. Children are included in such registries with parental permission. 
Permission may be given on the basis that the aim of the registry is to 
continue to learn about the condition and treatments for it or on a more 
open-ended basis, depending on the purpose of the registry. This 
permission includes data sharing on an ongoing basis, a process that is 
rendered increasingly seamless with electronic medical records.  However, 
even when registries may continue to collect data from the records of 
identifiable patients, efforts may not be made to inform or to re-consent 
patients at the time they reach adulthood. Thus, patients may be unaware 
that data about them rest in and are used by — or even continue to be 
shared with — registries. 
 
* Ph.D., J.D., Distinguished Alfred C. Emery Professor of Law and Distinguished Professor of 
Philosophy, University of Utah. 
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Such proliferation of registries poses potential concerns. These include 
poor security practices, data-repurposing, data linkages that enrich 
information available about individuals and may enable re-identification of 
data without identifiers, and re-contacts that patients find distressing. Even 
when individuals are not directly affected, they may be indirectly affected by 
registry findings or uses. Patients with a particular disease may be greatly 
benefited by research from registries, even if they are not in the registries 
themselves. Or, patients may be stigmatized by registry findings if they are 
part of a group about whom inferences are drawn — reasonably or 
unreasonably — whether or not they are part of the registry. Thus, patients 
arguably have interests in knowing that they are included in registries, as 
well as what registries are doing with the information they hold. 
This essay begins with a very brief overview of privacy laws and 
regulations applicable to registries. It then presents a sketch of some of the 
types and likely features of registries involving conditions manifest in infancy 
or early childhood. The account includes a description of the amount and 
kinds of data found in some registries, the uses made of the data, ongoing 
collection practices, policies about data sharing, and opportunities for data 
linkage. It is not a comprehensive survey, but an overview of some relevant 
registry features. The essay then continues with a description of a variety of 
adult notification or consent processes currently in use, either about data 
already collected or about ongoing data collection processes. The essay 
concludes by recommending transparency about registry practices for data 
collection and use and a requirement for re-consent when data are used in 
ways that do not fall within the original purpose of the registry. For registries 
that do not collect further information after children become adults but that 
continue to use or disclose data to other researchers, it recommends efforts 
to contact participants who have become adults and offer an opt-out 
possibility to the extent practicable, under clear standards for practicability. 
Registries that collect information on an ongoing basis should be required to 
re-consent patients after they have reached adulthood. As this is an 
exploratory essay, these recommendations are offered for further study, both 
about registry practices and about the ethical principles and regulations that 
should apply to them. 
II.  APPLICABLE LAWS AND REGULATIONS 
Depending on their purpose, data contained, and location, registries 
may be subject to a complex mix of privacy and confidentiality laws and 
regulations. These rules are highly technical and not always consistent; this 
summary presents aspects of the rules that are most relevant to the problem 
of information concerning children. Most important are the federal rules 
regarding research with human subjects, the Health Insurance Portability 
and Accountability Act (HIPAA) privacy rule governing protected health 
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information, the Federal Trade Commission (FTC) Act, and state privacy and 
confidentiality laws. This section provides a very brief overview of the most 
relevant provisions of each. Although many registries are international in 
scope, this discussion is limited to United States law only.1 
The federal rules governing research with human subjects apply formally 
to registries used for research concerning drugs or devices and research that 
is federally funded.2 These rules are for the most part consolidated into the 
“Common Rule.”3 Importantly, some registries may not themselves involve 
the systematic collection of data for generalizable knowledge but instead 
function as umbrellas collecting patient information that researchers then 
may use for research; in such cases the individual studies are research, but 
the registries themselves are not and thus do not come under the Common 
Rule. Under the Common Rule, human subjects are only living individuals 
from whom information is collected directly or about whom identifiable 
information is collected.4 In addition, research is exempt if data are 
collected from records identifying individuals in such a manner that subjects 
cannot be identified directly or through linking identifiers.5 Individual 
informed consent is required for inclusion in human subjects research unless 
consent has been waived or altered by the relevant Institutional Review 
Board (IRB).6 Consent may be waived if an IRB finds that the “research 
involves no more than minimal risk to the subjects,” the “waiver . . . will not 
adversely affect the rights and welfare of the subjects,” “the research could 
not practicably be carried out without the waiver or alteration,” and if 
“appropriate the subjects will be provided with additional pertinent 
information after participation.”7 This provision is commonly interpreted by 
IRBs to permit waiver of informed consent for the creation of large limited 
data sets, for studies involving chart review of completed care, and 
increasingly for other studies involving existing information without any 
contact with the persons it concerns.8 
 
 1. For a proposal for international standards, see Edward S. Dove et al., An Ethics Safe 
Harbor for International Genomics Research? 5 GENOME MEDICINE 99 (2013). 
 2. See REGISTRIES FOR EVALUATING PATIENT OUTCOMES: A USER’S GUIDE 3, 167 (Richard E. 
Gliklich et al. eds., 2d ed. 2010) [hereinafter USER’S GUIDE]. 
 3. 45 C.F.R. pt. 46 (2013). The scope of this section can be found at 45 C.F.R. § 
46.101 (2013). 
 4. 45 C.F.R. § 46.102(f) (2013). 
 5. 45 C.F.R. § 46.101(b)(4) (2013). 
 6. 45 C.F.R. § 46.116(c) (2013). 
 7. 45 C.F.R. § 46.116(d) (2013). 
 8. See U.S. DEPT. HEALTH & HUMAN SERVS., SUBPART A SUBCOMM., SECRETARY’S ADVISORY 
COMM. ON HUMAN RESEARCH PROTECTIONS (SACHRP), RECOMMENDATIONS REGARDING THE 
PROVISIONS FOR WAIVER OR ALTERATION OF THE INFORMED CONSENT REQUIREMENTS UNDER DEPT. 
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For children involved in research funded by HHS, the Common Rule 
requires parental (or guardian) permission and, if appropriate, assent from 
the child.9 For minimal risk research — which registries typically are — 
consent from one parent suffices;10 thus, in circumstances in which parents 
are separated or do not communicate, one parent may be unaware that the 
other has entered a child into a registry. The regulations also require assent 
if the children’s age, maturity, and psychological state so warrant; although 
this determination is left up to individual IRBs, it is unlikely that assent will be 
needed from children who have not yet entered elementary school.11 In 
addition, the exemption for data collected from records in such a manner 
that subjects cannot be identified directly or through linking identifiers 
applies to research involving children.12 The provisions for waiver or 
alteration of informed consent also apply to parental permission and child 
assent. The regulations are not explicit about whether there is need for 
consent at the point a child participating in a study becomes a legal adult in 
the jurisdiction in question. Guidance from the Office for Human Research 
Protection (OHRP), however, states that children becoming adults should be 
re-consented for any continuing interactions (including data collection) as 
well as for continuing data uses that would meet the criteria for human 
subjects research, unless a waiver is granted.13 Some IRBs specifically follow 
this guidance in their own policies.14 This is guidance, not formal regulation, 
 
HEALTH & HUMAN SERVS. (HHS) REGULATIONS AT 45 CFR 46.116(D), available at www.hhs.gov/ 
ohrp/archive/sachrp/mtgings/mtg07-07/present/WaiverConsentDocSAS.doc. 
 9. 45 C.F.R. § 46.404 (2013). 
 10. 45 C.F.R. § 46.408(b) (2013). 
 11. See 45 C.F.R. § 46.408(a) (2013) (stating that assent by children can be waived 
based on age and maturity level). As an example, the Penn State IRB cites an NIH panel in 
suggesting as guidelines a simple oral explanation and verbal assent from children age 6-7, a 
more complete oral explanation and documented verbal assent from children ages 8-12, and 
written assent thereafter, if the method is suitable to the child’s level of development. See 
PENN. ST. UNIV., OFFICE OF RESEARCH PROTECTIONS, IRB GUIDELINE I, PARENTAL CONSENT AND 
CHILD ASSENT (2007), available at http://www.research.psu.edu/policies/research-protections 
/irb/irb-guideline-1. Other IRBs provide written consent form templates for different ages. See, 
e.g., N.Y. UNIV. LANGONE MEDICAL CENTER, INSTITUTIONAL REVIEW BOARD, PROTOCOL / 
CONSENT / ASSENT / AUTHORIZATION TEMPLATES (2014) available at http://irb.med.nyu.edu/ 
consent. Still others provide a single assent template. See UNIV. OF UTAH, INSTITUTIONAL REVIEW 
BOARD, HEALTH SCIENCES FORMS TEMPLATES (2014), available at http://irb.utah.edu/forms/ 
health-sciences.php. 
 12. 45 C.F.R. § 46.401(b) (2013). 
 13. Research with Children – FAQs, U.S. DEPT. OF HEALTH & HUMAN SERVS, 
http://answers.hhs.gov/ohrp/categories/1570 (last visited Apr. 23, 2014). 
 14. See UNIV. TEXAS, OFFICE OF RESEARCH SUPPORT, SECTION 12: VULNERABLE POPULATIONS, 
available at http://www.utexas.edu/research/rsc/humansubjects/policies/section12.html#sec 
tion_12_4 (last visited Apr. 25, 2014). See also UNIV. OF UTAH, INSTITUTIONAL REVIEW BOARD, 
INVESTIGATOR GUIDANCE SERIES: ASSENT, available at http://irb.utah.edu/_pdf/IGS%20-
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however. Moreover, IRB willingness to grant waivers may vary and many 
registries are not within the formal scope of the federal regulations in any 
event. 
HIPAA requires patient authorization for release of protected health 
information.15 For purposes of this essay, protected health information can 
be understood to include individually identifiable health information, about 
living individuals or individuals who have died within the past 50 years, 
collected by a health care provider or payer.16 De-identified data are not 
protected under HIPAA17 and limited data sets may be released without 
authorization provided a data use agreement is in place.18 With approval 
from an IRB or a Privacy Board, HIPAA permits authorization to be waived 
for protected health information to be used in research.19 Criteria for a 
waiver include that the research is no more than minimal risk, that adequate 
protections of the information (including its destruction) are in place, that the 
research cannot practicably be conducted with if authorization is required, 
and that the research cannot practicably be conducted without the protected 
health information.20 One argument that the research cannot practicably be 
carried out if authorization is required is selection bias.21 HIPAA 
authorizations also are not required when protected health information is 
released to public health authorities as authorized by state law;22 state 
cancer or immunization registries are examples. Once granted, HIPAA 
authorizations remain in effect until revoked in writing unless action has 
been taken in reliance on them such as the use of the data in already-
conducted research.23 Although authorizations must specify an expiration 
date or event, authorizations for research may be for the duration of the 
research.24 An important difference between Common Rule consent and 
HIPAA authorization is that the former can be for quite general purposes 
whereas the latter requires more limited purpose specification; thus HIPAA 
authorizations may limit subsequent uses of registry information when the 
 
%20Assent.pdf (last visited Apr. 25, 2014). Utah specifies that a protocol amendment is 
required if adult consent forms were not included in the original research submission. Id. 
 15. Authorization Use & Disclosure, U.S. DEPT. HEALTH & HUMAN SERVS., http://www.hhs. 
gov/hipaafaq/use/264.html (last updated Mar. 14, 2006). 
 16. The full definition of protected health information can be found at 45 C.F.R. § 
160.103 (2013). 
 17. 45 C.F.R. §§ 164.502(d)(2), 164.514(a) (2013). 
 18. 45 C.F.R. § 164.514(e)(1) (2013). 
 19. 45 C.F.R. §§ 46.116(c)-(d) (2013). 
 20. 45 C.F.R. §§ 46.116(d)(1)-(4) (2013). 
 21. USER’S GUIDE, supra note 2, at 185. 
 22. 45 C.F.R. § 164.512(b)(2) (2013). 
 23. 45 C.F.R. § 164.508(b)(5)(1) (2013). 
 24. 45 C.F.R. § 164.508(c)(1)(v) (2013). 
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Common Rule does not.25 The HIPAA privacy rule defers to state law on 
identification of personal representatives26 and contains certain limits on 
disclosures of records of minors to their parents or guardians, but otherwise 
is silent on what happens to authorizations when children become adults. 
The HIPAA rules apply only so long as data are in the possession of a 
covered entity or its business associates; data collected by or transferred to 
registries outside the scope of HIPAA will not be HIPAA-protected even if it is 
individually identifiable, highly sensitive health information.27 Some such 
data, such as data in a limited data set, may continue to be protected by 
data use agreements; these are contractual arrangements and little is known 
about how they are monitored or enforced. One technical possibility is to 
meta-tag each element of disclosed data so that each particular disclosure 
can be identified; this would permit data to be traced in the case of a 
breach. 
The FTC Act prohibits unfair or deceptive trade practices by entities 
engaged in interstate commerce.28 It is a deceptive trade practice to give 
people false information about data collection practices or uses, including 
privacy and confidentiality policies. Increasingly, the FTC is scrutinizing data 
security and privacy practices that might expose individuals to significant 
risks against which they cannot readily protect themselves as unfair trade 
practices.29 Registries operating in the private sector are subject to these 
rules. 
Finally, a variety of state laws are relevant to privacy and consent to 
participation in registries; HIPAA sets a minimum floor and permits state 
laws to set more stringent privacy standards. These include state privacy laws 
such as California’s Online Privacy Protection Act that would apply to 
registries collecting information directly from patients residing in 
California.30 In Maryland, HIPAA authorizations may last for a maximum of 
one year only.31 In general, state statutes governing the power to consent to 
 
 25. USER’S GUIDE, supra note 2, at 182. This is a concern of the advance notice of 
proposed rulemaking concerning the Common Rule. See Human Subjects Research 
Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44,512, 44,523 (July 26, 2011) (to be codified at 
45 C.F.R. pts. 46, 160, 164 and 25 C.F.R. pts. 50, 56). 
 26. 45 C.F.R. § 164.502(g) (2013). See Leslie P. Francis, Skeletons in the Family Medical 
Closet: Access of Personal Representatives to Interoperable Medical Records, 4 ST. LOUIS U. J. 
HEALTH L. & POL’Y 371, 380-81 (2011). 
 27. USER’S GUIDE, supra note 2, at 173. 
 28. 15 U.S.C. § 45(a)(1) (2012). 
 29. TRENDnet, Inc.; Analysis of Proposed Consent Order to Aid Public Comment, 78 
Fed. Reg. 55,717, 55,718 (Sept. 11, 2013). 
 30. CAL. BUS. & PROF. CODE § 22575 (West Supp. 2014). 
 31. MD. CODE ANN., HEALTH-GEN. § 4-303(b)(4) (West 2013). 
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medical treatment also extend to the power to request medical records, and 
so these statutes would be relevant to information collected for registries 
when patients continue to be treated. These statutes authorize access to 
medical records, however, and do not also include provisions about 
whether an earlier authorization would need to be re-negotiated when a 
child reaches adulthood. 
III.  PATIENT REGISTRIES 
Patient registries are a widely used source of information about the 
clinical course of diseases, treatment safety and efficacy, care quality, and 
comparative effectiveness of interventions. This section presents a snapshot 
of some of the most relevant features of the ever-growing number of 
registries currently in existence and involving children. In 2010, the Agency 
for Healthcare Research and Quality published the second edition of their 
best practices User’s Guide for registries, a resource that contains a quite 
helpful discussion of models for registry design and implementation.32 
A. Registry Purpose 
Specification of a registry’s purpose is a primary recommendation of the 
User’s Guide.33 Purpose specification is critical to defining the scope, 
duration, and data collection practices of a registry. Purpose specification is 
also a long-recognized fair information practice principle, requiring that 
data subjects be informed about the uses to which identifiable data will be 
put and that significant changes require consent.34 
Registries have many stated purposes. Some registries are primarily 
umbrellas that can serve to identify potential participants for research studies 
but do not themselves conduct research. These registries then may approve 
particular research proposals and contact eligible registry participants to ask 
their permission to share contact information with the researchers. An 
example is the National Registry for Myotonic Dystrophy and 
Facioscapulohumeral Dystrophy, which contacts patients who are likely a 
candidate for approved studies about their interest before sharing 
 
 32. USER’S GUIDE, supra note 2, at iii. 
 33. USER’S GUIDE, supra note 2, at 23. 
 34. A seminal formulation of purpose specification reads: “There must be a way for an 
individual to prevent information about him obtained for one purpose from being used or 
made available for other purposes without his consent.” U.S. DEPT. HEALTH, EDUC. & WELFARE, 
RECORDS COMPUTERS AND THE RIGHTS OF CITIZENS: REPORT OF THE SECRETARY’S ADVISORY 
COMM. ON AUTOMATED PERSONAL DATA SYSTEMS 41 (1973). For a useful history of Fair 
Information Practices see Robert Gellman, Fair Information Practices: A Basic History, 
BOBGELLMAN.COM (Nov. 11, 2013), www.bobgellman.com/rg-docs/rg-FIPShistory.pdf. 
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information with researchers.35 Some registries, such as the Childhood 
Arthritis and Rheumatology Research Alliance juvenile rheumatoid arthritis 
registry, pool data from many individual researchers or clinicians to enrich 
the power of possible research.36 Some registries will share data for 
approved research in de-identified form, as limited data sets, or under 
waivers of informed consent and HIPAA authorization. Some of these 
registries defray costs in part by charging approved researchers for use of 
registry data.37 Some registries, such as the Cystic Fibrosis Foundation 
patient registry — now over 40 years old — are maintained by 
organizations devoted to particular diseases and may provide patient 
support, information about treatment and efficacy, and data for ongoing 
research.38 Others may collect data only about a particular intervention at a 
given point in time, such as a registry for children and adults undergoing 
cardiac catheterization39 or a registry for antiretroviral therapy during 
pregnancy.40 Still others are aimed to improve public health, such as state 
immunization registries. Some are designed to improve the health of 
children generally, such as Rhode Island’s KIDSNET which collects 
information on a wide range of characteristics of children’s health.41 
Registries have also been constructed to detect adverse events from the use 
of a variety of drugs or devices, such as the use of antiretrovirals in HIV-
positive pregnant women or the use of Celebrex in children. 
 
 35. See Frequently Asked Questions, UNIV. ROCHESTER MED. CTR., NAT’L REGISTRY FOR 
MYOTONIC DISTROPHY (DM) & FACIOSCAPULOHUMERAL DYSTROPHY (FSHD), www.urmc.roch 
ester.edu/neurology/national-registry/about-us/faq.cfm (last updated Feb. 21, 2014). 
 36. Marc D. Natter et al., The Childhood Arthritis & Rheumatology Research Alliance 
Network Registry: Demographics and Characteristics of the Initial 6-Month Cohort, PEDIATRIC 
RHEUMATOLOGY, July 13, 2012, at A57. Some of these registries defray costs in part by 
charging approved researchers for use of registry data. 
 37. An example is the non-profit National Birth Defect Registry for Children. See Research 
Data Project, BIRTH DEFECT RES. FOR CHILD, INC., www.birthdefects.org/research/datapro 
ject.php (last visited Apr. 8, 2014). 
 38. See CYSTIC FIBROSIS FOUND., 2012 PATIENT REGISTRY ANNUAL DATA REPORT 4-5 
(2012), available at www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegistryRe 
port/2012-CFF-Patient-Registry.pdf. 
 39. See, e.g., IMPACT Registry, NAT’L CARDIOVASCULAR DATA REGISTRY, https://www.ncdr. 
com/webncdr/impact (last visited Apr. 8, 2014) (collecting data about children and adults 
with congenital heart disease undergoing diagnostic catheterizations). 
 40. See Who We Are, ANTIRETROVIRAL PREGNANCY REGISTRY, www.apregistry.com (last 
visited Apr. 8, 2014). The registry collects information about the child at birth; however, it is 
unclear from information available online whether information is collected about the child 
after the perinatal period. The Registry is located in North Carolina and can be contacted at  
800-285-4263. 
 41. KIDSNET, R.I. DEPT. HEALTH, www.health.ri.gov/programs/kidnet/index.php (last 
visited Apr. 8, 2014). 
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B. Data Collection and Use 
One important distinguishing feature is the extent to which a registry 
collects information that could be used to identify individuals. Privacy and 
confidentiality laws historically have addressed only information that could 
be used to identify individuals. Thus the Privacy Act of 1974 places 
disclosure limitations on “records” containing identifying particulars,42 
HIPAA applies only to “health information” relating to individuals,43 and the 
Common Rule governing research considers human subjects only to include 
private information gained directly from or identifying living individuals.44 
Current controversy abounds over whether de-identification can ever be 
effectively protected, especially for types of information such as genetic 
information or when data sets are combined.45 Commentators argue that 
even if data remain de-identified, information about groups may be 
problematic to individual group members.46 It thus seems fair to say that the 
line between identifiable information and de-identified information is 
increasingly blurred. 
Although some registries collect only de-identified information, registries 
are far more useful if they contain information about patient identifiers 
sufficient to allow record linkages, contact information about patients for 
follow up, and residence location for geographic comparisons.47 Because 
specific diseases or interventions define many registries, risks of re-
identification from registry data are thought to be higher than with other 
types of de-identified data.48 Depending on the purpose of the registry, the 
User’s Guide recommends collection of such information as sexual history, 
reproductive history, overseas travel and citizenship, and other sensitive 
social history information, thus posing risks if individually identifiable 
information is released.49 Registries typically maintain such information in 
coded form, however, so that direct access to the registry will not reveal 
information about individual patients. When registries share information with 
others — for example, by giving researchers permission to use data in the 
 
 42. 5 U.S.C. §§ 522a(a)(4), 522(b) (2012). 
 43. 45 C.F.R. § 160.103 (2013) 
 44. 45 C.F.R. § 46.102(f) (2013). 
 45. Melissa Gymrekh et al., Identifying Personal Genomes by Surname Inference, 339 
SCI. 321, 321 (2013); Jordan Robinson, States’ Hospital Data for Sale Puts Privacy in 
Jeopardy, BLOOMBERG TECH. (June 4, 2013), http://www.bloomberg.com/news/2013-06-05/ 
states-hospital-data-for-sale-puts-privacy-in-jeopardy.html. 
 46. Mark A. Rothstein, Is Deidentification Sufficient to Protect Health Privacy in Research?, 
10 AM. J. BIOETHICS 3, 5 (2010). 
 47. USER’S GUIDE, supra note 2, at 108. 
 48. Id. at 147. 
 49. Id. at 111. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
398 SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY [Vol. 7:389 
registry — they typically also only share de-identified or limited data sets50 
under agreements that the researchers will not attempt to re-identify 
individuals.  Nonetheless, the increasingly blurred deidentification/ 
identification line means that privacy concerns about registry data in all of 
these forms cannot be ignored. 
Data in registries may be collected from many sources: patients 
themselves, family members, electronic medical records, insurance claims, 
and pharmacy records, among other sources.51 The increasing availability 
of information in electronic form makes information flow far more readily 
and seamlessly than when registry development depended on provider 
reporting from records maintained in paper form. The capability to submit 
data to immunization registries is a Meaningful Use Stage 1 menu 
objective,52 and the capability to submit data to state cancer registries is a 
Stage 2 menu objective.53 The result will be that registries will be able to 
gather impressive amounts of data from patient electronic health records, 
thus enabling these records to be used for purposes different from their 
original creation for patient care, and raising questions about the fair 
information practice principle of purpose specification if these data are 
compiled without patient consent. 
Data in registries may be linked in two different ways that are critically 
different from a privacy perspective. Horizontal linkage aggregates data by 
characteristics — for example, an immunization and subsequent seizure.54 
Publication of aggregate statistics such as the percentage of children 
receiving particular immunizations and having subsequent seizures does not 
pose enhanced risks for identifying individuals. Vertical linkage, by contrast, 
links data to individuals — for example, a patient’s medical record with 
physician prescribing information with administrative data about pharmacy 
claims that would show whether the patient filled a prescription. Vertical 
linkage presents far greater privacy concerns than horizontal linkage, as a 
 
 50. A “limited data set” is defined under HIPAA to mean a data set that includes no 
identifying information except date of service, town or city, state, and ZIP code. See 45 C.F.R. 
§ 164.514(e)(2) (2013). 
 51. USER’S GUIDE, supra note 2, at tbl. 8. 
 52. Eligible Professional Meaningful Use Menu Set Measures: Measure 9 and 10, CTRS. 
MEDICARE & MEDICAID SERVS., http://www.cms.gov/Regulations-and-Guidance/Legislation/ 
EHRIncentivePrograms/downloads/9_Immunization_Registries_Data_Submission.pdf (last 
updated April 2013). 
 53. Stage 2 Overview Tipsheet, CTRS. MEDICARE & MEDICAID SERVS., http://www.cms. 
gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Downloads/Stage2Over 
view_Tipsheet.pdf (last updated Aug. 2012). 
 54. Michael Gold et al., Use of the Australian Childhood Immunisation Register for 
Vaccine Safety Data Linkage, 28 VACCINE 4308, 4309 (2010). 
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vertically linked data-base will contain more information about each 
individual than the data bases independently.55 
C. Sponsorship 
Primary funding sources for registries are state public health agencies, 
academic medical centers and other treatment groups, non-profit 
organizations devoted to particular conditions, or commercial entities 
interested in drug or device development. Immunization registries, cancer 
registries, and a variety of registries concerning children’s health are 
maintained by public health agencies. Pittsburgh Children’s Hospital 
maintains a registry devoted to research on diabetes in children, for 
example.56 The Cystic Fibrosis Foundation is one of many disease-based 
non-profits maintaining a registry aimed to improve treatment and 
conditions for patients with the disorder of interest.57 The Children’s 
Cardiomyopathy Foundation maintains a registry in cooperation with the 
National Heart, Lung, and Blood Institute.58 Genzyme, a company with 
commercial interests in developing therapies for genetic diseases, sponsors 
registries for the lysosomal storage diseases Fabry,59 Gaucher, 60 and 
Pompe.61 Pfizer maintained a registry to study the long-term safety of 
treatment with its nonsteroidal anti-inflammatory Celebrex that included 
children ages 2-17; the registry was terminated after changes in treatment 
recommendations.62 
 
 55. USER’S GUIDE, supra note 2, at 147. 
 56. Children’s Hospital Diabetes Research Center Registry, CHILD. HOSP. PITT., 
http://www.chp.edu/CHP/Diabetes+Research+Center+Registry+Study (last updated Mar. 7, 
2014). 
 57. See CYSTIC FIBROSIS FOUND., PATIENT REGISTRY ANNUAL DATA REPORT (2012), 
available at www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegistryReport/20 
12-CFF-Patient-Registry.pdf. 
 58. Patient Registry, CHILD. CARDIOMYOPATHY FOUND., http://www.childrenscardiomyo 
pathy.org/site/registry.php (last visited Apr. 15, 2014). One can contact the Foundation and 
its registry through Nicole Turcotte at 617-972-3045. 
 59. Fabry Registry, FABRY COMMUNITY, http://www.fabrycommunity.com/en/Healthcare/ 
Registry.aspx (last visited Apr. 15, 2014). 
 60. Understanding Gaucher Disease, GAUCHER REGISTRY, https://www.registrynxt.com/ 
Gaucher/Pages/Home.aspx (last visited Apr. 15, 2014). 
 61. Treating and Researching Pompe Disease, POMPE REGISTRY, https://www.registry 
nxt.com/Pompe/Pages/Home.aspx (last visited Apr. 15, 2014). 
 62. Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) and NSAIDs in Juvenile 
Idiopathic Arthritis (SINCERE), CLINICALTRIALS.GOV (May 6, 2014), http://clinicaltrials.gov/ 
show/NCT00688545. 
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IV.  PERMISSION AND CONSENT PRACTICES 
Registries represent very different approaches to parental permission and 
implementation of assent or consent requirements as children age. Some 
registries simply cease to collect data after the age of legal adulthood, but 
may continue to allow use of previously collected data. Some registries 
require adult consent for continued participation. Other registries apparently 
allow parental permission to ongoing collection of data without re-consent 
when the child becomes an adult. 
At one end of the spectrum are registries that require adult consent for 
continuing participation in the registry. An example is the registry of children 
diagnosed with cancer maintained by the Children’s Cooperative Oncology 
Group.63 This registry contains the records of 37,629 patients diagnosed 
with cancer as children; 96% of the patients were treated at cooperating 
institutions since full inception of the registry in 2007.64 The registry follows 
children long-term and is an impressive resource for longitudinal outcome 
data. At the point patients in the registry reach 18, they are contacted for 
consent to continued participation in the registry; if they cannot be reached 
or if they decline continued participation, their data are no longer made 
available to researchers.65 Another example of a registry reportedly requiring 
re-consent is the National Registry for Myotonic Dystrophy and 
Facioscapulohumeral Dystrophy; adults who refuse continued participation 
thus are not contacted by this umbrella registry to request their interest in 
participating in any further studies.66 Some IRBs have explicit policies 
requiring re-consent to continuing participation in studies at the point of 
adulthood, unless a waiver is approved.67 Others require re-consent (absent 
waiver) for ongoing data collection or other interventions but apparently not 
for research with data collected during minority.68 A draft white paper for a 
proposed third edition of the User’s Guide reports that the federal OHRP 
interprets the federal regulations to require re-consent at the point of 
adulthood for ongoing registry participation.69 
 
 63. Childhood Cancer Research Network (CCRN) CCRN – Considering Registration, 
CHILDREN’S ONCOLOGY GROUP, http://www.childrensoncologygroup.org/index.php/child 
hood-cancer-research-network-ccrn (last updated Aug. 21, 2013). 
 64. Id. 
 65. Id. 
 66. Yaffa R. Rubinstein et al., Informed Consent Process for Patient Participation in Rare 
Disease Registries Linked to Biorepositories, 33 CONTEMPORARY CLINICAL TRIALS 5, 7 (2012). 
 67. The University of Texas re-consent policy follows the ORHP guidance explicitly. See 
UNIV. OF TX., supra note 11. 
 68. UNIV. UTAH, INSTITUTIONAL REVIEW BOARD, INVESTIGATOR GUIDANCE SERIES: ASSENT, 
available at http://irb.utah.edu/_pdf/IGS%20-%20Assent.pdf (last visited Apr. 21, 2014). 
 69. U.S. DEPT. HEALTH & HUMAN SERVS., AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, 
INFORMED CONSENT FOR PATIENT REGISTRIES: DRAFT WHITE PAPER FOR THIRD EDITION OF 
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At the other end of the spectrum are registries that continue data 
collection activity after the age of legal adulthood, operating under parental 
permission and authorization without any apparent requirement for re-
consent. The Partners HealthCare registry for its Down syndrome patients 
would appear to be an example. The goal of the registry is to understand 
what conditions co-occur with Down, as patients with this condition are 
living far longer lives. Permission to participate in the registry lasts for the 
child’s lifetime or until the parent chooses to withdraw the child or the child 
chooses to withdraw.70 The consent form is explicit that data may be 
collected from past, present, and future medical records; will be identifiable; 
and may be shared with participating researchers.71 There is no indication 
that patients will be re-contacted or re-consented at the time they reach 
adulthood, although the study is quite clear that data will continue to be 
collected as long as patient is treated at a participating institution. Another 
example of apparently open-ended permission is the type one 
neurofibromatosis registry at Washington University, which allows parents to 
authorize release of their children’s medical information “until end of 
study.”72 
With the advent of biobanks linking tissue samples, genetic information, 
and patient records, research has attempted to ascertain patients’ attitudes 
towards re-consent to participation at the point of adulthood. One study 
assessed patients’ attitudes towards a hypothetical scenario involving the 
continued use of samples and data stored in pediatric biobanks.73 The study 
finding was that two thirds would not be concerned about the use of their 
samples and data after they reached adulthood.74 Almost half (46%) 
believed that their consent should be obtained; three quarters of these 
would be moderately or highly willing to give consent when asked.75 Just 
over one-quarter would not be willing to have their data used without their 
 
“REGISTRIES FOR EVALUATING PATIENT OUTCOMES: A USER’S GUIDE” (2011), available at 
http://www.effectivehealthcare.ahrq.gov/ehc/products/423/975/Informed-Consent-for-Pa 
tient-Registries_DraftReport.pdf. 
 70. PARTNERS HEALTH SYSTEM, PARENT TEMPLATE: DOWN SYNDROME PATIENT REGISTRY 
RESEARCH CONSENT FORM 2 (2010), available at http://www.massgeneral.org/children/assets/ 
pdf/down-syndrome-registry-consent-form.pdf. 
 71. Id. 
 72. WASHINGTON UNIV. SCH. MED. IN ST. LOUIS, AUTHORIZATION RELEASE OF MEDICAL 
INFORMATION, available at https://nf1registry.wustl.edu/graphics/Authorization-for-Release-of-
Medical-Information.pdf (last visited Apr. 1, 2014). 
 73. Aaron J. Goldenberg et al., Pediatric Biobanks: Approaching Informed Consent for 
Continuing Research after Children Grow Up, 155 J. PEDIATRICS 578, 578-83 (2009). 
 74. Id. at 579. 
 75. Id. 
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consent.76 Interestingly, only 16% thought that de-identification of data 
made a difference as to their need for or willingness to give consent.77 
African-Americans were 2.7 times more likely to be concerned about the use 
of their data than white respondents.78 As this study involved not only data 
but also biological samples, it may over-represent the likelihood of concern 
about the use of data collected during childhood. Another potential 
limitation of the study is that it involved a hypothetical scenario; it was not 
an assessment of the attitudes of patients whose samples had actually been 
included in biobanks. The authors of the study conclude that these findings 
may reflect the desire to participate in decision-making about research, 
rather than objection to the research itself.79 Nonetheless, the fact that one-
quarter of patients would not want their information used without their 
consent should give pause about continuing data use into adulthood. Other 
studies indicate that patients are more concerned about commercial uses of 
data than about public health or research uses.80 
V.  RECOMMENDATIONS 
This section presents recommendations for further study and 
consideration about re-consent of patients in registries when they reach 
adulthood. It recommends transparency about registry practices for data 
collection and use and re-consent when data are used in ways that do not 
fall within the original purpose of the registry. For registries that do not 
collect further information after children become adults but that continue to 
use or disclose data to other researchers, it recommends efforts to contact 
participants who have become adults and offer an opt-out possibility to the 
extent practicable, under clear standards for practicability. Registries that 
collect information on an ongoing basis should be required to re-consent 
patients after they have reached adulthood. 
The User’s Guide emphasizes transparency as a means of fostering 
trust.81 In some cases, it states that public disclosure of registry activities, 
such as when a section on a registry web page gives patients information 
about registry activities, may serve as an alternative to forms of consent.82 
 
 76. Id. at 580. 
 77. Id. 
 78. Goldenberg et al. supra note 73, at 581. 
 79. Id. at 579. See also REBECCA SKLOOT, THE IMMORTAL LIFE OF HENRIETTA LACKS (2010). 
Of note, the data for this study were collected in 2002-2003, while The Immortal Life of 
Henrietta Lacks was published in 2009. 
 80. Evette J. Ludman et al., Glad You Asked: Participants’ Opinions of Re-Consent for 
dbGaP Data Submission, J. EMPIRICAL RES. HUM. RES. ETHICS, Sept. 2010, at 9, 14. 
 81. USER’S GUIDE, supra note 2, at 189. 
 82. Id. at 190. 
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For patients who are aware of the existence of a registry and the possibility 
that their information may be included in it, these websites may serve to alert 
them to possible data uses. In addition, it may provide them with 
information about disease discoveries, possibilities for participation in 
research, and patient support opportunities that might be of value to them. 
As an example, the University of Pittsburgh diabetes registry lists all active 
studies on its website.83 Many disease-based registries such as the Cystic 
Fibrosis Foundation list a wide variety of information for patients and patient 
supports on their websites.84 If use of data from individuals creates any 
obligations of reciprocity to those whose data are used — as arguably it 
does — then such transparency about potentially beneficial registry activities 
may be ethically required. 
Registries that no longer collect information but that continue to allow 
data to be used should contact participants who have become adults and 
offer an opt-out possibility to the extent practicable, under clear standards 
for practicability, as recommended by the OHRP. This should include opting 
out for future uses of data, as well as for re-contact for consent to 
participate in future studies. Because registries may be highly valuable, 
arguably when participants cannot be contacted their data may continue to 
be used under circumstances in which IRBs grant waivers of consent. 
However, these waivers may be granted only if the research cannot 
practicably be conducted with consent or without the data and there should 
be clear standards for what practicability requires. “Practicably” is a 
technical legal term that means more than just costly or difficult. In contract 
law, obligations are voidable for impracticability, which requires changed 
circumstances that could not reasonably have been anticipated at the time 
the contract was made, that undermine a basic assumption of the parties, 
and that make performance unreasonably expensive or difficult.85 Applied to 
registry participation, this would require subsequent changes in 
understanding that could not reasonably have been anticipated at the time 
of registry initiation, that alter needs for data collection and use, and that 
make re-consent or elimination of the data unreasonably expensive or 
difficult. An example might be important new research with registry data 
when sampling bias would be introduced by exclusion of participants who 
cannot be located for re-consent. 
 
 83. Type 1 Diabetes Clinical Studies, CHILD. HOSP. PITT., http://www.chp.edu/CHP/type+ 
1+diabetes+clinical+trials (last visited Apr. 1, 2014). See also Type 2 Diabetes Clinical 
Studies, CHILD. HOSP. PITT., http://www.chp.edu/CHP/type+2+diabetes+clinical+trials (last 
visited Apr. 1, 2014). 
 84. Patient Registry Report, CYSTIC FIBROSIS FOUND., http://www.cff.org/livingwithcf/quali 
tyimprovement/patientregistryreport (last visited Apr. 9, 2014). 
 85. RESTATEMENT (SECOND) OF CONTRACTS § 261 (1979). 
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Re-contact may be troubling for some registry participants. In addition to 
not knowing about their inclusion in the registry if their parents did not 
inform them, participants may not even know that they had the condition 
that identified them for registry entry. Or, they may regard this as a closed 
chapter in their lives that they wish never to remember. If re-contact is not 
conducted with great care, others may become aware of the registry 
participation or condition when the patient would not wish them to be so 
informed. 
Finally, any continued data collection for registry use clearly requires re-
consent on the part of competent adult participants in the registry. In order 
to continue to acquire medical information, the registry must perforce have 
contact information from the patient through his/her provider obtaining the 
information. To minimize distress, this re-consent should be the responsibility 
of the provider of the medical information. 
VI.  CONCLUSION 
Registries are an enormously valuable resource for research, healthcare, 
quality measurement, comparative effectiveness measurement, public 
health, adverse event surveillance, and other purposes. Many registries 
concern conditions manifest in childhood and include participants who were 
entered without their knowledge on the basis of permission from their 
parents or guardians. Data in these registries may pose risks or concerns to 
participants and to the extent practicable they should be re-consented at 
adulthood for continuing registry participation. As registry participants are 
living longer and data sets are enriched, these risks may only increase. 
Further study of how registries work and how re-consent practices might be 
implemented is warranted. 
 
